#United States #Washington #Vanda Pharmaceuticals #Fanapt #Hetlioz

Vanda Pharmaceuticals Reports Strong Q3 2026 Financial Results

Vanda Pharmaceuticals Inc. has made headlines with its impressive financial performance in the third quarter of 2026, revealing a 24% increase in total revenues, reaching $69.8 million compared to the same period last year. This upswing is even more pronounced when looking at the comparison to the previous quarter, with revenues up 38% from Q2 2026. These figures reflect the successful positioning and momentum of Vanda’s product lineup, particularly the growth of Fanapt and the early revenue contributions from the recently launched NEREUS™ product.

Financial Overview

In addition to the revenue growth, Vanda has also reported a 18% reduction in total operating expenses, bringing them down to $93.3 million compared to Q2 2026. This decrease is attributed to the conclusion of key Phase III clinical trials and preparations for product launches. As a leading biopharmaceutical company, Vanda's strategic initiatives have resulted in substantial cost savings, which is critical as they continue to navigate the competitive market landscape.

Dr. Mihael H. Polymeropoulos, Vanda’s President and CEO, expressed his satisfaction with these results, stating, "We are pleased with the strong revenue growth in the third quarter, driven by continued Fanapt momentum and the early contribution from our NEREUS commercial launch."

Product Breakdown

The financial report highlights a $38.8 million revenue from Fanapt, marking a 24% increase from Q3 2025. Meanwhile, revenues for HETLIOZ reached $21.7 million — a 21% increase compared to the previous year and a striking 289% increase since Q2 2026. PONVORY showed moderate growth with revenues of $7.7 million, reflecting a 10% rise year-over-year.

Recently, the newly launched NEREUS™ made significant strides in sales, earning $1.6 million in Q3 2026, which is a 60% increase from the second quarter. This product aims to address medical needs in motion-induced vomiting, and Vanda is focused on expanding its market presence.

Looking Ahead

Turning the spotlight to the future, Vanda anticipates the launch of BYSANTI™, expected in the fourth quarter of 2026, targeting treatment for bipolar I disorder and schizophrenia. The company is also awaiting FDA's decision on the biologics license application for Quimilza™, which is currently under review with a PDUFA target action date of December 12, 2026.

In recent clinical developments, Vanda has reported positive Phase III study results for NEREUS™, generating optimism for its potential approval in preventing vomiting associated with GLP-1 receptor agonist therapy. Additionally, the results from trials surrounding HETLIOZ for Delayed Sleep-Wake Phase Disorder indicate a promising trajectory for future application.

Vanda’s investment in its product pipeline, transparency in financial reporting, and continued commitment to addressing unmet medical needs are paving the way for further success. The company maintains an optimistic outlook for 2026, updating its revenue guidance to project total revenues exceeding $240 million for the year.

Conference Call and Future Announcements

Vanda Pharmaceuticals has scheduled a conference call to discuss these results and additional corporate activities. This interactive session allows stakeholders and investors to engage with the company’s management team, further addressing inquiries regarding future developments and expectations. The call is set for the evening of October 28, 2026.

In summary, Vanda Pharmaceuticals is making significant strides in the biopharmaceutical landscape, successfully increasing revenue significantly while managing costs effectively. Looking forward to the upcoming product launches and regulatory decisions, the company is positioned to enhance its brand reputation and market share in the health sector, thereby improving outcomes for patients across various spectrums of care.